Brokerages Set Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Price Target at $32.00

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $32.00.

ODTX has been the topic of several analyst reports. Wedbush initiated coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price target on the stock. Wall Street Zen cut Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. JPMorgan Chase & Co. assumed coverage on Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “overweight” rating and a $26.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 target price on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Finally, Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd.

Insider Buying and Selling

In related news, Director Nan (Ln) Li bought 1,111,111 shares of the company’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $18.00 per share, with a total value of $19,999,998.00. Following the transaction, the director owned 3,333,516 shares in the company, valued at approximately $60,003,288. This trade represents a 50.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tpg Gp A, Llc bought 1,388,889 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $25,000,002.00. Following the completion of the transaction, the insider owned 3,690,146 shares in the company, valued at $66,422,628. This trade represents a 60.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 4,183,777 shares of company stock worth $75,319,986 over the last ninety days.

Odyssey Therapeutics Price Performance

ODTX opened at $18.66 on Wednesday. The firm’s fifty day simple moving average is $17.45. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $20.30.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its earnings results on Wednesday, June 17th. The company reported ($6.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($5.46).